Verastem, Inc. (VSTM)
NASDAQ: VSTM · Real-Time Price · USD
5.55
+0.25 (4.72%)
At close: Apr 1, 2026, 4:00 PM EDT
5.48
-0.07 (-1.22%)
After-hours: Apr 1, 2026, 7:59 PM EDT
Verastem Employees
Verastem had 102 employees as of December 31, 2025. The number of employees increased by 24 or 30.77% compared to the previous year.
Employees
102
Change (1Y)
24
Growth (1Y)
30.77%
Revenue / Employee
$303,078
Profits / Employee
-$2,053,637
Market Cap
487.48M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 102 | 24 | 30.77% |
| Dec 31, 2024 | 78 | 5 | 6.85% |
| Dec 31, 2023 | 73 | 16 | 28.07% |
| Dec 31, 2022 | 57 | 9 | 18.75% |
| Dec 31, 2021 | 48 | 0 | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Lyell Immunopharma | 300 |
| Entrada Therapeutics | 152 |
| Absci | 140 |
| Nautilus Biotechnology | 130 |
| Kyverna Therapeutics | 129 |
| enGene Holdings | 82 |
| Assembly Biosciences | 73 |
| Larimar Therapeutics | 71 |
VSTM News
- 13 days ago - Verastem: Maintaining "Buy" As 1st Half 2026 Catalysts In Play - Seeking Alpha
- 15 days ago - Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026 - Business Wire
- 15 days ago - Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancers - Business Wire
- 4 weeks ago - Verastem, Inc. (VSTM) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates - Business Wire
- 6 weeks ago - Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 - Business Wire
- 2 months ago - Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers - Business Wire
- 2 months ago - Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire